Overview

Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
To determine the activity of lenalidomide in relapsed or refractory aggressive NHL.
Phase:
Phase 2
Details
Lead Sponsor:
Celgene Corporation
Collaborator:
Prologue Research International
Treatments:
Lenalidomide
Thalidomide